Trial Profile
Phase I Dose Escalation Study of Radiotherapy and Durvalumab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions
- Acronyms RaDD
- 11 Apr 2024 Status changed from active, no longer recruiting to completed.
- 05 Feb 2024 Planned End Date changed from 1 Dec 2023 to 30 Jun 2024.
- 29 Nov 2022 Planned End Date changed from 1 Feb 2023 to 1 Dec 2023.